Algoritmo De Selección De Receptores Altamente Sensibilizados En Lista De Espera Modalidad Donante Fallecido En Panamá. 2021
[Selection Algorithm for Highly Sensitized Recipients On The Waiting List Deceased Donor Modality In Panama. 2021]Alejandro Vernaza-Kwiers1, Luis Ortiz2, Juan Moscoso3, Yina Gutierrez3, Cesar Cuero4
1. Laboratorio Nacional de Trasplante; 2. Laboratorio Nacional de Trasplante, Rep de Panamá; 3. Laboratorio Nacional de Trasplante, República de Panamá; 4. Organización Panameña de Trasplante Rep de Panamá;
Descargas
Resumen
El Sistema de antígenos de Leucocitos Humanos (HLA) juega un papel funcional en la presentación de péptidos al sistema Inmune. El grado de compatibilidad de los antígenos de los leucocitos humanos (HLA) de los loci -A, -B, -DRB1 entre el receptor en lista de espera y el donante, y la ausencia de anticuerpos específicos contra los antígenos HLA del donante, tienen la mejor sobrevida en un trasplante. El nuevo algoritmo de selección de receptores sensibilizados en lista de espera, que se introduce en el presente trabajo, tiene como objetivo mejorar su posibilidad de recibir riñones provenientes de un donante fallecido. Este algoritmo cumple etapas que se siguen en la selección del receptor sensibilizado compatible con el donante fallecido. Previo a incorporar un paciente en la lista de espera, es requisito conocer el grado de sensibilización a los antígenos del sistema de Leucocitos Humanos (HLA). El Laboratorio Nacional de Trasplante ha incorporado el Panel Reactivo de Anticuerpos Calculado (cPRA) que utiliza la frecuencia de antígenos HLA de la población panameña, en sustitución del Panel Reactivo de anticuerpos (PRA) que utiliza la frecuencia de alelos de otra población que no es la panameña.
Abstract
The Human Leukocyte Antigen (HLA) system plays a functional role in the presentation of peptides to the immune system. The degree of compatibility of human leukocyte antigens (HLA) loci -A, -B, -DRB1 between the waiting list recipient and the donor, and the absence of specific antibodies against the donor HLA antigens, have the best survival in transplantation. The new algorithm for the selection of sensitized recipients on the waiting list, introduced in the present work, aims to improve their chance of receiving kidneys from a deceased donor. This algorithm fulfills stages that are followed in the selection of the sensitized recipient compatible with the deceased donor. Before adding a patient to the waiting list, it is a requirement to know the degree of sensitization to the antigens of the Human Leukocyte Antigen System (HLA). The National Transplant Laboratory has incorporated the Calculated Reactive Panel of Antibodies (cPRA) that uses the frequency of HLA antigens of the Panamanian population, replacing the Reactive Panel of Antibodies (PRA) that uses the frequency of alleles of another population that is not Panamanian.
Citas
[1] Patel R., Terasaki PL. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-9. DOI: http://dx.doi.org/10.1056/NEJM196904032801401 URL: https://doi.org/10.1056/NEJM196904032801401
[2] McKenna RM., Takemoto SK., Terasaki PL. Anti HLA antibodies after solid organ transplantation. Transplantation 2000; 69:319-326. URL: https://doi.org/10.1097/00007890-200002150-00001
[3] Susal C., Opelz G. Impact of HLA matching and HLA antibodies in organ transplantation. A collaborative transplant study view. Methods Mol. Biol. 2012; 882: 267-77. URL: https://doi.org/10.1007/978-1-61779-842-9_15
[4] Sumitran Helgerson S. HLA specific antibodies and renal allograft outcome. Nephrol dial Transplant 2001, 10: 897-904. URL:https://doi.org/10.1093/ndt/16.5.897
[5] Cecka J., Zhang R., Reed F. Preformed citotoxic antibodies in potential allograft recipients' recent data. Human Immunol 2005; 4:343-9. URL:https://doi.org/10.1016/j.humimm.2005.01.030
[6] Yang J., Schael C., Smith D, et al. Sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of Luminex. Heart Lung Transplant 2009; 28:123-9. URL:https://doi.org/10.1016/j.healun.2008.11.908
[7] Lee PC, Ozawa M, Hung CJ, et al. Reappraisal of the HLA antibody analysis and crossmatching in kidney transplantation. Transplant Proc. 2009; 41:95-9. URL: https://doi.org/10.1016/j.transproceed.2008.10.074
[8] Muro M., Llorente S., Marin L., et al. Acute vascular rejections mediated by HLA antibodies in a cadaveric kidney recipient; discrepancies between Flow RRA, ELISA, and CDC vs Luminex screening. Nephrol Dial Transplant. 2009; 20:223-6. URL:https://doi.org/10.1093/ndt/gfh527
[9] Jung S., Oh EJ., Yang CW. et al. Comparative evaluation of ELISA and Luminex Panel Reactive Antibody assay for HLA alloantibody screening. Korean J Lab Med. 2009; 29:423-480. URL: https://doi.org/10.3343/kjlm.2009.29.5.473.
[10] Howell WM., Carter V., Clark B. The HLA System Immunobiology. HLA typing antibody screening and crossmatching techniques. J Clin Pathol 2010; 63:390. URL: https://doi.org/10.1136/jcp.2009.072371
[11] Cecka JM., Kucheryavaya AV, Reinsmoen NL., Leffell MS. Calculated PRA: initial results show benefits for sensitized patients and reduction in positive crossmatches. Am. J. Transplant 2011; 11:719-724. URL: https://doi.org/10.1111/j.1600-6143.2010.03340.x
[12] Cecka JM. Calculated PRA (cPRA) the new measure of sensitization for transplant candidates. Am J Transplant 2012;1026-29
[13] 13.- Duquesnoy R, Marrari M, et al. Workshop report a website for the antibody defined HLA epítope registry. International Journal for Immunogenetics 2012;0:1-6.
[14] Marrari M., Muistecki J., Mulder a, et al. Human monoclonal Antibody reactivity with HLA Class I. epítopos defined by pairs of mismatched Eplets and Self Eplets. Transplantation 2012; 90: 1468-72. URL:https://doi.org/10.1097/TP.0b013e3182007b74
[15] Llanes A, Vernaza A, et al. Allele and frequencies in the Panamanian Population. URL:http://doi.org/10.1016/j.humimm,2020, 11. 006
[16] Cherikh W. Variability of PRA levels and reporting of unacceptable antigens among transplant centers. Report to the Histocompatibility Committee on January 2006 of an analysis of OPTN/UNOS data.
[17] Zachary AA and Braun WE. Calculation of a predictive value for 71: 268-273.
[18] Lefell MS, Kaplan I, Zachary AA. The probability of a positive crossmatch is a more accurate measure of sensitization and benefits minorities. Abstract 766. World Transplant Congress 2006. Blackwell Publishing Malden, MA, page 325. URL: https://doi.org/10.1097/00007890-200607152-00766
[19] Duquesnoy RJ. Humoral autoimmunity in transplantation: relevance of HLA epítopo antigenicity and immunogenicity. Front Immunology 2011; 2, 59. URL:https://doi.org/10.3389/fimmu.2011.00059
[20] Meneses GP, Melo R, et al. An online data base of predicted three-dimensional structure of HLA molecules. Human Immunol URL:https://doi.org/10-1016 Humimm 2019, 06, 009.
[21] Morris GP, Phelan D, Jemdrisak M, et al. Virtual crossmatch identification of donor specific anti-human leukocyte antigen antibody by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation. Human Immunology 2010; URL:https://doi.org/10.1016/j.humimm.2010.01.003
Licencia
Derechos de autor 2021 Infomedic Intl.Derechos autoriales y de reproducibilidad. La Revista Médica de Panama es un ente académico, sin fines de lucro, que forma parte de la Academia Panameña de Medicina y Cirugía. Sus publicaciones son de tipo acceso gratuito de su contenido para uso individual y académico, sin restricción. Los derechos autoriales de cada artículo son retenidos por sus autores. Al Publicar en la Revista, el autor otorga Licencia permanente, exclusiva, e irrevocable a la Sociedad para la edición del manuscrito, y otorga a la empresa editorial, Infomedic International Licencia de uso de distribución, indexación y comercial exclusiva, permanente e irrevocable de su contenido y para la generación de productos y servicios derivados del mismo. En caso que el autor obtenga la licencia CC BY, el artículo y sus derivados son de libre acceso y distribución.
